This is a working overview of rodent models, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-22. Anything still debated is marked as such rather than presented as settled.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
| Property | Value | Notes |
|---|---|---|
| Amino acid count | 15 residues | Synthetic pentadecapeptide chain |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Molecular formula | C62H98N16O22 | Free peptide, without counter-ion |
| Theoretical mass | Approximately 1419.5 daltons | Varies slightly with adducts and counter-ions |
| Origin | Fragment of a human gastric juice protein | Source of the BPC designation |
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
Historically, it was used in folk medicine to treat jaundice and as a natural dye source for textiles. More recently, it has become a subject of astrobiology research, where it survives Mars-like environments, space vacuum, cosmic radiation, and extreme cold. This resilience has established X. parietina as a model organism in both environmental monitoring and space exploration research.
He currently serves as a member of the board of directors of the International Chemical Biology Society. He also served as the director (officiating) of Bose Institute during the critical Centenary year. In addition, Roy played the very crucial role as an advisory committee member to successfully conduct the 'International Conference on Genome Biology 2019' hosted by the School of Biological Sciences (SBS), Madurai Kamaraj University.
== Criminal trial == After being delayed for more than a year due to the COVID-19 pandemic, Vaught's trial began on March 21, 2022. Prosecutors portrayed the use of the override function as evidence of recklessness. On the other hand, defense experts testified that overrides were daily events at many hospitals, and Vaught testified that Vanderbilt's 2017 upgrade of its computer systems had caused such delays that nurses were instructed to use overrides to get medication that they needed. A Tennessee Bureau of Investigation agent testified that the medical center had a "heavy burden of responsibility" for the deadly medication error, but that the Bureau of Investigation only pursued criminal charges and penalties against the nurse, not the hospital. After Murphey's death, the hospital did not report the error to federal or state regulators (as required by law) and reported to the county medical examiner that Murphey died of natural causes with no mention of the vecuronium. The hospital also negotiated an out-of-court settlement with Murphey's family which prevents them from disclosing details of her death. On March 25, 2022, the jury convicted Vaught of gross neglect of an impaired adult and negligent homicide, which carries a maximum sentence of eight years in prison. She was acquitted of the more serious charge of reckless homicide. On May 13, 2022, Judge Jennifer Smith ruled that Vaught would not have to spend time in prison, sentencing her instead to three years' probation.
First, in a series of Commission decisions, Google and Amazon were fined for competition violations. In the Google Shopping case, the Commission fined Google €2.4 billion for giving preference to its own shopping results over others in Google's search, leading to huge increases in traffic for Google over rivals. In the Google Android case the Commission fined Alphabet Inc (by then Google's rebranded parent name) €4.34 billion, or 4.5% of worldwide turnover, for paying phone manufacturers to pre-install its apps, such as Google search or Chrome, as a condition to license its app marketplace Google Play. In the Google AdSense case, the Commission fined Google €1.49 billion for stopping third-party websites displaying their adverts in Google's embedded search widgets, given that it was dominant in the ad market, and unfairly excluding competitors from results. In the Amazon Marketplace case an investigation for abuse of dominant position was launched for Amazon using other traders' data to benefit its own retail business, and preferencing itself in its "Buy Box" and in access to "Prime" seller status. This was settled after Amazon committed in 2022 "not to use non-public data relating to, or derived from, the independent sellers' activities on its marketplace, for its retail business", and to not discriminate against third parties in its Buy Box and Prime services. The Digital Markets Act codifies many of these standards.
Sources: en.wikipedia.org
== History == Sports energy gels emerged in the United Kingdom in 1986 as a "convenient, prewrapped, portable" way to deliver carbohydrates during endurance events. Gels have a gooey texture and are sometimes referred to as "goo" generically. The gel Leppin Squeezy was distributed at the Hawaii Ironman Triathlon in 1988. Once considered a "cult product in clear packaging", energy gel products are now marketed in fancy packaging and come in a variety of flavors. The energy gel market grew during the 1990s, as professional athletes began endorsing products. Manufacturers generally encourage the consumption of multiple packets, with water, when participating in endurance events.
=== Natural abundance === Although it is rare on Earth, helium is the second most abundant element in the known Universe, constituting 23% of its baryonic mass. Only hydrogen is more abundant. The vast majority of helium was formed by Big Bang nucleosynthesis one to three minutes after the Big Bang. As a result, measurements of its abundance contribute to cosmological models. The first molecular bonds were formed when primordial helium atoms combined with protons to form helium hydride ions, HeH+. In stars, helium is formed by the nuclear fusion of hydrogen in proton–proton chain reactions and the CNO cycle, part of stellar nucleosynthesis. In the Earth's atmosphere, the concentration of helium by volume is only 5.2 parts per million. The concentration is low and fairly constant despite the continuous production of new helium because most helium in the Earth's atmosphere escapes into space by several processes. In the Earth's heterosphere, a part of the upper atmosphere, helium and hydrogen are the most abundant elements. Most helium on Earth is a result of radioactive decay. Helium is found in large amounts in minerals of uranium and thorium, such as uraninite and its varieties cleveite and pitchblende, as well as carnotite and monazite (a group name; "monazite" usually refers to monazite-(Ce)), because they emit alpha particles (helium nuclei, He2+) to which electrons immediately combine as soon as the particle is stopped by the rock. In this way an estimated 3000 metric tons of helium are generated per year throughout the lithosphere.
== Prokaryotic == Prokaryotes use one type of RNA polymerase, transcribing mRNAs that code for more than one type of protein. Transcription, translation and mRNA degradation all happen simultaneously. Transcription termination is essential to define boundaries in transcriptional units, a function necessary to maintain the integrity of the strands and provide quality control. Termination in E. coli may be Rho dependent, utilizing Rho factor, or Rho independent, also known as intrinsic termination. Although most operons in DNA are Rho independent, Rho dependent termination is also essential to maintain correct transcription. ρ factor The Rho protein is an RNA translocase that recognizes a cytosine-rich region of the elongating mRNA, but the exact features of the recognized sequences and how the cleaving takes place remain unknown. Rho forms a ring-shaped hexamer and advances along the mRNA, hydrolyzing ATP toward RNA polymerase (5' to 3' with respect to the mRNA). When the Rho protein reaches the RNA polymerase complex, transcription is terminated by dissociation of the RNA polymerase from the DNA. The structure and activity of the Rho protein is similar to that of the F1 subunit of ATP synthase, supporting the theory that the two share an evolutionary link. Rho factor is widely present in different bacterial sequences and is responsible for the genetic polarity in E. coli. It works as a sensor of translational status, inhibiting non-productive transcriptions, suppressing antisense transcriptions and resolving conflicts that happen between transcription and replication.
== Controversies == In 2010, BioMarin became involved in controversy surrounding 3,4-diaminopyridine (3,4-DAP). BioMarin markets a phosphate salt of 3,4-DAP under the name Firdapse. In 2010, BioMarin was granted exclusive licensing rights to Firdapse for 10 years. As a result, the price of a prescribed National Health Service treatment course has increased from $1,987 for the unlicensed drug to $69,970 for Firdapse. The company states that prior to its licensing, there was no guaranteed quality control of the product and no way of formally monitoring for uncommon side effects through the regulatory process. In 2013, BioMarin Pharmaceuticals was at the center of a high-profile debate regarding expanded access of cancer patients to experimental drugs. On the advice of her doctor, Andrea Sloan, a patient with advanced ovarian cancer, requested that the company provide her with access to BMN 673, an unapproved PARP inhibitor drug candidate that had exhibited promising activity in a small Phase 1 clinical trial. The company declined, citing safety concerns. Ms. Sloan eventually received a similar drug candidate from a different company. In 2015, there was another controversy over expanded access, concerning the supply of a drug on clinical trial to a German child who was suffering from a brain disorder but who was not part of the trial. In April 2019, the BBC reported that patients who took part in a trial treatment for the drug Kuvan (sapropterin hydrochloride) were later denied access to it.
Crocetta is crossed by large and modern avenues, such as Corso Duca degli Abruzzi, Corso Galileo Ferraris, and Corso Einaudi. These avenues feature long rows of trees, symbolic of Turin's typical urbanity. However, the most popular avenue is Corso De Gasperi, which, albeit smaller than other avenues of the district, hosts one of the most fashionable open markets of the city, the so-called Mercato della Crocetta, in which it is possible to find some discounted branded clothing among the more popular ones. The Western border of Crocetta is instead an example of contemporary architecture. The huge avenue, made up of Corso Mediterraneo and Corso Castelfidardo, is part of Spina Centrale boulevard and was recently built over the old railway (now undergrounded): as a result, the avenue is very large (up to 60 m (200 ft)) and modern, having been rebuilt with valuable materials, including a characteristic lighting system supported by white high poles. This avenue hosts some examples of contemporary art, such as Mario Merz's Igloo fountain or the Per Kirkeby's Opera per Torino monument in Largo Orbassano. The East side of the district is also known as Borgo San Secondo named after the church of the same name standing in Via San Secondo, a major street in the neighbourhood. This is near Porta Nuova railway station and is older than the rest of the district, featuring several apartment buildings from the late 19th century, to include the birthplace and home of author Primo Levi on Corso Re Umberto. A local open market is held in Piazza San Secondo and along Via Legnano.
Sources: en.wikipedia.org
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.
Rodents account for the large majority of published experiments. Human data are sparse and mostly observational, so cross-species extrapolation remains uncertain.
It is not an approved therapeutic in most jurisdictions. Regulatory status varies by country, and several places restrict it as a research chemical.
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.